Education
About Us
Working with TipRanks
Follow Us
Telix Pharmaceuticals Ltd. (AU:TLX)
ASX:TLX
TLX Stock Chart & Stats
AU$11.23
-AU$0.59(-2.38%)
At close: 4:00 PM EST
AU$11.23
-AU$0.59(-2.38%)
Day’s Range― - ―
52-Week RangeAU$8.26 - AU$29.72
Previous CloseN/A
Volume456.62K
Average Volume (3M)3.11M
Market Cap
AU$3.81B
Enterprise ValueAU$4.34B
Total Cash (Recent Filing)AU$212.74M
Total Debt (Recent Filing)AU$785.24M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Aug 20, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding338,891,050
10 Day Avg. Volume3,089,243
30 Day Avg. Volume3,113,251
Financial Highlights & Ratios
PEG Ratio2.81
Price to Book (P/B)6.08
Price to Sales (P/S)3.04
P/FCF Ratio-44.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$23.82Price Target Upside112.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)0.03
Revenue Forecast (FY)AU$959.11M
Bulls Say, Bears Say
Bulls Say
Market AccessAnalyst's recommendation reflects confidence that a two-product PSMA PET diagnostic strategy will expand market access by appealing to payors with differing reimbursement preferences.
Pipeline FundingAnalyst highlights that diagnostic revenue growth is expected to be reinvested into the therapeutics pipeline to advance lead oncology candidates toward pivotal trials and future approvals.
Regulatory CatalystAnalyst views the anticipated resubmission of the brain imaging agent Pixclara to US regulators as a potential catalyst toward approval that would add a major product to the US commercial portfolio.
Bears Say
Product PerformanceAnalyst notes softness in legacy restless legs syndrome products, which poses a headwind to overall revenue growth.
Regulatory And Legal RiskAnalyst classifies the investment as high risk due to dependence on regulatory approvals, guideline placement, resolution of safety data issues, and an ongoing SEC inquiry that could create uncertainty.
Valuation PressureReduction of the price target signals tempered valuation expectations and may weigh on investor sentiment.
Telix Pharmaceuticals News
TLX FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest share price was AU$8.26 and its highest was AU$29.72 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is AU$3.81B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 160 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Feb 19, 2026. The company reported -AU$0.017 earnings per share for the quarter, missing the consensus estimate of AU$0.057 by -AU$0.074.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is 0.02.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 338,891,050 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of -AU$0.017 in its last earnings report, missing expectations of AU$0.057. Following the earnings report the stock price went up 14.239%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:TLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Telix Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$23.82 (112.10% Upside)
AU$23.82 (112.10% Upside)
Blogger Sentiment
Bullish
AU:TLX Sentiment 93%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 79%
Bearish news 11%
Bearish news 11%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.98%
12-Months-Change
Fundamentals
Return on Equity
-2.08%
Trailing 12-Months
Asset Growth
25.10%
Trailing 12-Months
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
TLX Company Deck
TLX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance in terms of revenue growth, product expansion, and strategic acquisitions, highlighting the company's robust cash position and pipeline advancements. However, challenges such as SEC inquiries, gross margin pressure, and competitive pricing pressures were noted.View all AU:TLX earnings summariesTLX Stock 12 Month Forecast
Average Price Target
AU$23.82
▲(112.10% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Mesoblast Limited
―
Neuren Pharmaceuticals Limited
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Options Prices
Currently, No data available
---